Qubigen Wraps Up BIO 2025 with Over 40 Strategic Meetings and High-Impact Engagements
- David Brooks
- Jul 4
- 1 min read
Qubigen has concluded a highly productive week in Boston focused on partnering and collaboration, highlighted by CEO Jonathan Hall’s presentation at the BIO International Convention 2025.
Dr. Jonathan Hall, Founder & CEO and Dr. Sonya Diakiw, Founder & CSO, represented Qubigen at BIO 2025, engaging with a broad spectrum of academic institutions, industry stakeholders, and global pharmaceutical leaders.
Highlights from the Event
Over 40 meetings with potential collaborators, clients, and strategic partners, including formal partnering sessions and informal meetings, with many follow-up discussions already underway.
A well-received company presentation that introduced Qubigen’s Federated AI capabilities in drug development, highlighting past successful drug development use cases, and showcasing Qubigen’s Collaborator Platform.
Multiple exclusive industry reception events that facilitated deeper conversations with prospective collaborators and clients.
Throughout the week, Qubigen's privacy-preserving, AI-driven approach to molecular design attracted interest from a diverse group of organizations seeking to collaborate on difficult targets, advance under-utilized data assets, or employ novel hit identification strategies.
The momentum from these engagements is already translating into follow-up conversations, formal collaborations, and pilot project scoping. We look forward to sharing more as these discussions progress.
As always, Qubigen remains committed to enabling secure, collaborative drug development by helping partners unlock the full potential of their scientific data—without compromising confidentiality or IP.
Qubigen - accelerate drug design without exposing secrets
Whether you're advancing active programs, reviving dormant data, or starting from scratch, Qubigen’s secure AI platform and virtual screening capabilities can help you identify, optimize, and accelerate the path to promising lead drug candidates. Get in touch to explore how we can support your next development.
